Literature DB >> 28240157

Editorial: Current and Emerging Therapeutics in AD.

Marwan Sabbagh1, Boris Decourt2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28240157      PMCID： PMC5705184          DOI： 10.2174/156720501404170217182758

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN： 1567-2050            Impact factor:   3.498


× No keyword cloud information.
  15 in total

1.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

Authors:  Rachelle S Doody; Rema Raman; Martin Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Feng He; Xiaoying Sun; Ronald G Thomas; Paul S Aisen; Eric Siemers; Gopalan Sethuraman; Richard Mohs
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

2.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Authors:  Rachelle S Doody; Ronald G Thomas; Martin Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Rema Raman; Xiaoying Sun; Paul S Aisen; Eric Siemers; Hong Liu-Seifert; Richard Mohs
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

Review 3.  Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

Authors:  Francesco Panza; Giancarlo Logroscino; Bruno P Imbimbo; Vincenzo Solfrizzi
Journal:  Curr Opin Psychiatry       Date:  2014-03       Impact factor: 4.741

Review 4.  Conformation as the Therapeutic Target for Neurodegenerative Diseases.

Authors:  Rajaraman Krishnan; Franz Hefti; Haim Tsubery; Michal Lulu; Ming Proschitsky; Richard Fisher
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

5.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

Review 6.  Deep Brain Stimulation for Alzheimer's Disease.

Authors:  David S Xu; Francisco A Ponce
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 7.  Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.

Authors:  David Hsu; Gad A Marshall
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 8.  Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer's Disease.

Authors:  Asante R Kamkwalala; Paul A Newhouse
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

9.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Authors:  Robert C Green; Lon S Schneider; David A Amato; Andrew P Beelen; Gordon Wilcock; Edward A Swabb; Kenton H Zavitz
Journal:  JAMA       Date:  2009-12-16       Impact factor: 56.272

Review 10.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease.

Authors:  J Hardy; D Allsop
Journal:  Trends Pharmacol Sci       Date:  1991-10       Impact factor: 14.819
View more
  2 in total

Review 1.  Technological Solutions for Diagnosis, Management and Treatment of Alzheimer's Disease-Related Symptoms: A Structured Review of the Recent Scientific Literature.

Authors:  Davide Maria Cammisuli; Gabriele Cipriani; Gianluca Castelnuovo
Journal:  Int J Environ Res Public Health       Date:  2022-03-07       Impact factor: 3.390

2.  Syndecan-3 as a Novel Biomarker in Alzheimer's Disease.

Authors:  Anett Hudák; Annamária Letoha; Csaba Vizler; Tamás Letoha
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.